ERBB2 and breast cancer: the preoperative use of systemic therapy with curative intent (i.e. neoadjuvant chemotherapy (NCT)) has become the standard of care for locally advanced BC and early stage human epidermal growth factor receptor-type 2 positive (HER2+) or triple negative BC (TNBC)5–7.